Nicotine-induced neuroprotection against ischemic injury involves activation of endocannabinoid system in rats

Neurochemical Research

Volumn 38, Issue 2, 2013, Pages 364-370

  Chen, Yu ^a   Nie, Huang ^a   Tian, Li ^a   Tong, Li ^a   Yang, Lujia ^a   Lao, Ning ^a   Dong, Hailong ^a   Sang, Hanfei ^a   Xiong, Lize ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cannabinoid; Cerebral ischemia; Nicotine

Indexed keywords

2 ARACHIDONOYLGLYCEROL; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; N ARACHIDONYLETHANOLAMINE; NICOTINE TARTRATE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN TISSUE; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; REPERFUSION; UPREGULATION;

ANIMALS; BRAIN; BRAIN ISCHEMIA; ENDOCANNABINOIDS; MALE; NEUROPROTECTIVE AGENTS; NICOTINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; UP-REGULATION;

RATTUS;

EID: 84876409051     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0927-6     Document Type: Article

References (29)

1. Borlongan CV, Shytle RD, Ross SD, Shimizu T, Freeman TB, Cahill DW, Sanberg PR (1995) Nicotine protects against systemic kainic acid induced excitotoxic effects. Exp Neurol 136:261-265
2. Baron JA (1986) Cigarette smoking and Parkinson's disease. Neurology 36:1490-1496
3. Morens DM, Grandinetti A, Reed D, White LR, Ross GW (1995) Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45:1041-1051
4. Ciobica A, Padurariu M, Hritcu L (2012) The effects of short-term nicotine administration on behavioral and oxidative stress deficiencies induced in a rat model of Parkinson's disease. Psychiatr Danub 24:194-205
5. Viveros MP, Marco EM, Llorente R, Lamota L (2007) The role of the hippocampus in mediating emotional responses to nicotine and cannabinoids: a possible neural substrate for functional interactions. Behav Pharmacol 18:375-389
6. Gamaleddin I, Wertheim C, Zhu AZ, Coen KM, Vemuri K, Makryannis A, Goldberg SR, Le Foll B (2012) Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol 17:47-61
7. Merritt LL, Martin BR, Walters C, Lichtman AH, Damaj MI (2008) The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 326:483-492
8. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987-2995
9. Hayakawa K, Irie K, Sano K, Watanabe T, Higuchi S, Enoki M, Nakano T, Harada K, Ishikane S, Ikeda T, Fujioka M, Orito K, Iwasaki K, Mishima K, Fujiwara M (2009) Therapeutic time window of cannabidiol treatment on delayed ischemic damage via high-mobility group box1-inhibiting mechanism. Biol Pharm Bull 32:1538-1544
10. Wang Q, Peng Y, Chen S, Gou X, Hu B, Du J, Lu Y, Xiong L (2009) Pretreatment with electroacupuncture induces rapid tolerance to focal cerebral ischemia through regulation of endocannabinoid system. Stroke 40:2157-2164
11. Hata R, Mies G, Wiessner C, Fritze K, Hesselbarth D, Brinker G, Hossmann KA (1998) A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab 18:367-375
12. Garcia JH, Wagner S, Liu KF, Hu XJ (1995) Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke 26:627-634
13. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM (1986) Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17:1304-1308
14. Patel S, Rademacher DJ, Hillard CJ (2003) Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 306:880-888
15. Nanri M, Kasahara N, Yamamoto J, Miyake H, Watanabe H (1997) GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol 74:285-289
16. Decker MW, Majchrzak MJ, Anderson DJ (1992) Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res 572(1-2):281-285
17. Gao ZG, Cui WY, Zhang HT, Liu CG (1998) Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice. Pharmacol Res 38(2):101-106
18. Stevens Tanya R, Krueger Stefan R, Fitzsimonds Reiko M, Picciotto Marina R (2003) Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and L-type calcium channel inactivation. J Neurosci 3:10093-10099
19. Belluardo N, Mudo G, Blum M, Fuxe K (2000) Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res 113:21-34
20. Akaike A, Takada-Takatori Y, Kume T, Izumi Y (2010) Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection. J Mol Neurosci 40(1-2):211-216
21. Quik M, Perez XA, Bordia T (2012) Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 27(8):947-957
22. Takarada T, Nakamichi N, Kawagoe H, Ogura M, Fukumori R, Nakazato R, Fujikawa K, Kou M, Yoneda Y (2012) Possible neuroprotective property of nicotinic acetylcholine receptors in association with predominant upregulation of glial cell line-derived neurotrophic factor in astrocytes. J Neurosci Res 90(11):2074-2085
23. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, Shohami E (2006) The endocannabinoid 2-AG protects the blood- brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22:257-264
24. Ma L, Zhu Z, Zhao Y, Hou L, Wang Q, Xiong L, Zhu X, Jia J, Chen S (2011) Cannabinoid receptor type 2 activation yields delayed tolerance to focal cerebral ischemia. Curr Neurovasc Res 8:145-152
25. Amantea D, Spagnuolo P, Bari M, Fezza F, Mazzei C, Tassorelli C, Morrone LA, Corasaniti MT, Maccarrone M, Bagetta G (2007) Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J 274:4464-4775
26. Degn M, Lambertsen KL, Petersen G, Meldgaard M, Artmann A, Clausen BH, Hansen SH, Finsen B, Hansen HS, Lund TM (2007) Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice. J Neurochem 103:1907-1916
27. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531
28. Pacher P, Hasko G (2008) Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153:252-262
29. Biala G, Kruk M (2008) Cannabinoid receptor ligands suppress memory-related effects of nicotine in the elevated plus maze test in mice. Behav Brain Res 192:198-202